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ARTICLE
An HDAC9-MALAT1-BRG1 complex mediates
smooth muscle dysfunction in thoracic aortic
aneurysm
Christian L. Lino Cardenas 1,2,3, Chase W. Kessinger2,3, Yisha Cheng1,2,3, Carolyn MacDonald1,2,3,
Thomas MacGillivray1,4, Brian Ghoshhajra1,5, Luai Huleihel6,7, Saifar Nuri1,2,3, Ashish S. Yeri3,
Farouc A. Jaffer 2,3, Naftali Kaminski 7, Patrick Ellinor 2,3,8, Neal L. Weintraub9, Rajeev Malhotra2,3,
Eric M. Isselbacher1,2,3 & Mark E. Lindsay1,2,3,8,10
Thoracic aortic aneurysm (TAA) has been associated with mutations affecting members of
the TGF-β signaling pathway, or components and regulators of the vascular smooth muscle
cell (VSMC) actomyosin cytoskeleton. Although both clinical groups present similar phe-
notypes, the existence of potential common mechanisms of pathogenesis remain obscure.
Here we show that mutations affecting TGF-β signaling and VSMC cytoskeleton both lead to
the formation of a ternary complex comprising the histone deacetylase HDAC9, the
chromatin-remodeling enzyme BRG1, and the long noncoding RNA MALAT1. The
HDAC9–MALAT1–BRG1 complex binds chromatin and represses contractile protein gene
expression in association with gain of histone H3-lysine 27 trimethylation modiﬁcations.
Disruption of Malat1 or Hdac9 restores contractile protein expression, improves aortic mural
architecture, and inhibits experimental aneurysm growth. Thus, we highlight a shared epi-
genetic pathway responsible for VSMC dysfunction in both forms of TAA, with potential
therapeutic implication for other known HDAC9-associated vascular diseases.
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Hereditary thoracic aortic aneurysm (TAA) can be medi-ated by genetic variation and numerous causal genes havenow been associated with the phenotype1–3. Several
classes of genetic perturbation are directly tied to the function of
vascular smooth muscle cells (VSMCs). One group includes genes
encoding members of the canonical transforming growth factor-β
(TGF-β) signaling cascade (exempliﬁed by the Marfan syndrome
and Loeys-Dietz syndrome) and are known collectively as TGF-β
vasculopathies (TGFβVs). This class of genetic perturbations
includes mutations in the genes FBN1, TGFB2, TGFB3, TGFBR1,
TGFBR2, SMAD2, SMAD3, and SKI4–10. The second major group
of mutations involves genes encoding component members of the
smooth muscle contractile apparatus (Smooth Muscle Contrac-
tion Vasculopathies, SMVCs). Gene defects in SMCVs include
mutations in the actin-myosin pair: α-smooth muscle actin
(encoded by ACTA2) and smooth muscle myosin heavy chain
(encoded by MYH11)11–13, as well as genes encoding regulators
of the actin-myosin interaction, PRKG1 and MYLK14,15. In fact,
considering that mutations in genes that deﬁne VSMC identity
mediate TAA, this phenotype should rightly be considered as a
cardinal manifestation of smooth muscle cell dysfunction.
Described human genetic variation indicates that perturbations
that either negatively inﬂuence canonical TGF-β signaling, or
alternatively disrupt vascular smooth muscle cell (VSMC) con-
traction, result in impaired aortic homeostasis. Despite the
functional dissimilarity of these gene groups, patients with
TGFβVs and SMCVs display similar anatomic distributions of
aortic disease, progressive aortic enlargement, and pathologic
elastin fragmentation with loss of markers of contractile smooth
muscle cell phenotype11,16. On the basis of phenotypic similarity,
we reasoned that a shared disease mechanism was discoverable
through mutual pathway perturbation and comparison of
observed effects.
Herein we show that in the presence of diverse genetic per-
turbations affecting VSMC cytoskeletal stability, the class IIa
histone deacetylase HDAC9 is upregulated, concentrates in the
nucleus, and joins into a novel chromatin-remodeling complex
with the brahma-related gene 1 protein (BRG1) and the long
noncoding RNA (lncRNA) MALAT1. We ﬁnd the complex
associated with repressive chromatin marks at the promoters of
key cytoskeletal genes, and inhibition of HDAC9 function relieves
disease-associated transcriptional repression. MALAT1 is neces-
sary for targeting HDAC9 to the nucleus and depletion of
MALAT1 or HDAC9 reverses deleterious cellular phenotypes and
modiﬁes VSMC-dependent pathology including inhibiting
experimental aortic aneurysm. We show that HDAC9, in coop-
eration with BRG1 and MALAT1, mediates a critical epigenetic
pathway responsible for VSMC dysfunction. These data offer the
ﬁrst mechanistic link between the two major categories of human
genetically triggered aortic aneurysm (TGFβVs and SMCVs), and
have therapeutic implications for treatment of not only aortic
aneurysm, but also other HDAC9-associated human vascular
diseases involving VSMC function, including hypertension17,
intracranial aneurysms18, ischemic stroke19, and myocardial
infarction20.
Results
TAA-related genetic perturbations upregulate HDAC9. To
investigate shared transcriptional perturbations we created a
cellular system using human aortic VSMCs to mimic loss-of-
function genetic variation associated with the TAA phenotype.
The genes SMAD3 and TGFB2 (TGFβVs) as well as ACTA2 and
MYH11 (SMVCs) fulﬁlled this criterion and were selected for
speciﬁc siRNA targeting after proven bioactivity (Fig. 1a and
Supplementary Fig. 1a). Of 42542 genes examined, microarray
gene expression analysis demonstrated 44 genes dysregulated in
the same direction for both siSMAD3-treated and siACTA2-
treated cells with a greater than 1.5-fold change (Fig. 1b, Sup-
plementary Fig. 1b). Analysis of the interactome and disease-
related network on the 44-dysregulated genes identiﬁed HDAC9,
SMAD4, PTGFR, and PRKCE as the highest scoring genes within
the cardiovascular disease category (Supplementary Data 1,
Supplementary Fig. 1c). HDAC9 was validated and selected for
further examination due to its implication in diverse forms of
human vascular disease18–20. Quantitative PCR (qPCR) analysis
of siSMAD3, siTGFB2, siACTA2 and siMYH11 treated cells
conﬁrmed upregulation of total HDAC9 (Fig. 1c) and individual
HDAC9 transcript isoforms (Supplementary Fig. 1d). To extend
these observations, we next modeled two aggressive forms of
hereditary TAA, by lentiviral expression in human aortic VSMCs,
TGFR2G357W, a severe Loeys-Dietz syndrome TGFβV21 and
ACTA2R179H, causing a severe SMCV22. Dramatic upregulation
of HDAC9 was observed in both of these experimental condi-
tions, but not when wild-type versions were overexpressed
(Fig. 1d, Supplementary Fig. 1e&f). In the presence of these alleles
HDAC9 demonstrates increased nuclear localization (Fig. 1e).
Cells from aortic aneurysms have been noted to have migratory
abnormalities as well as upregulation of matrix degrading
enzymes, such as MMP2 and MMP923,24. Expression of the
TGFR2G357W or ACTA2R179H alleles in VSMCs induced
increased MMP catalytic activity as well as inhibition of activity
in wound healing assays, both of which could be suppressed by
silencing of HDAC9 (Fig. 1f, g). Conversely, wound healing assay
inhibition could be induced through overexpression of HDAC9/
MITR (Supplementary Fig. 1g&h). Similar to cellular models,
HDAC9 was found to be grossly upregulated in surgical samples
from TAA patients (Fig. 1h). Immunohistochemistry from TAA
samples also showed upregulation of HDAC9 in aneurysm tissue
from syndromic, sporadic, and familial cases of TAA (Fig. 1i,
Supplementary Data 2).
Both the observed deﬁciency in wound healing assays and
induction of MMP activity are reminiscent of phenotypes
induced by actin cytoskeletal destabilization25. We therefore
chose to visualize the actin cytoskeleton in our experimental
model. Notably, an apparent loss of F-actin content was a shared
feature of TGFR2G357W and ACTA2R179H transduced VSMCs
(Fig. 2a). Similarly, expression of several VSMC contractile
proteins was decreased (Fig. 2b, Supplementary Fig. 2a). As
previously observed in murine aneurysm models26 the expression
of coﬁlin-1, an important negative regulator of actin polymeriza-
tion, was upregulated. A similar decrease in ﬁlamentous actin
staining and decrement in contractile protein expression (SM22α)
is observed in human TAA tissue taken at the time of surgery
(Fig. 2c). Consistent with this observation, a decrease in the ratio
of F-actin to G-actin is a shared feature of TGFR2G357W and
ACTA2R179H transduced VSMCs (Fig. 2d). To determine
whether modulation of the actin cytoskeleton could also directly
induce the expression and mobilization of HDAC9, we treated
VSMCs with the actin toxin latrunculin (1 µM) and the toxin
phalloidin (1 µM). Latrunculin (an actin destabilizing agent),
induced robust expression as well as rapid nuclear accumulation
of HDAC9, whereas phalloidin (an actin stabilizing agent) did not
(Supplementary Fig. 2b).
HDAC9 joins a complex with BRG1 and the lncRNA
MALAT1. While several other HDAC isoforms demonstrated
transcriptional upregulation, only HDAC9 demonstrated clear
upregulation at the protein level (Fig. 3a, Supplementary Fig. 3a).
To gain insight into cellular events in TGFR2G357W and
ACTA2R179H transduced VSMCs, we analyzed HDAC9 via a
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network analysis (Supplementary Fig. 3b). This revealed the close
association of HDAC9 with BRG1 (Brahma-related gene 1), an
association noted previously in cardiomyocytes27. These data are
consistent with previous observations of BRG1 upregulation in
TAAs28 and involvement of BRG1 in VSMC phenotypic mod-
ulation29,30. We therefore chose to test for a physical interaction
between these proteins. Indeed, HDAC9 strongly associates with
BRG1 immunoprecipitates and the interaction is increased in the
presence of TAA-associated alleles (Fig. 3b). Given that BRG1 has
a known capability to interact with nucleic acids through intrinsic
binding activity31,32, we hypothesized that the HDAC9–BRG1
complex may associate with nuclear RNAs to regulate chromatin-
remodeling events. To address this question we performed
genome-wide proﬁling of HDAC9–BRG1 interactions with RNA
using UV crosslinking with high-throughput sequencing analysis
(CLIP-seq) from HDAC9 and BRG1 immunoprecipitates in
VSMCs. We detected 217 transcripts that associated with HDAC9
and BRG1 at either baseline conditions, or in the presence of the
TGFR2G357W or ACTA2R179H alleles, while 107 core transcripts
bound the complex under all three conditions (Fig. 3c and Sup-
plementary Data 3). Pathway analysis of the core transcripts
revealed them to be thematically involved in EIF2 signaling,
remodeling of cell-cell junctions, as well as actin cytoskeletal
signaling (Fig. 3c, Supplementary Fig. 3c&d, and Supplementary
Data 4). At least two RNAs represented genes directly implicated
with aortic disease in humans, FBN14 and LRP133. In addition to
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mRNA detection, a single lncRNA was associated with the
immunoprecipitates under all experimental conditions, the evo-
lutionarily conserved RNA, MALAT1 (Supplementary Fig. 3e).
To test the ﬁdelity of this association, we analyzed HDAC9 and
BRG1 immunoprecipitates for binding activity to a panel of
known cardiovascular lncRNAs (Fig. 3d). Of these RNAs, only
MALAT1 was found to associate speciﬁcally with both HDAC9
and BRG1 in CLIP–qPCR assays (Fig. 3e). To test whether
MALAT1 bound to HDAC9 or BRG1 individually or within an
HDAC9–BRG1 complex, we performed serial immunoprecipita-
tion followed by reverse transcription PCR (RT–PCR) analysis for
MALAT1. This assay demonstrated that MALAT1 can be
detected associated with HDAC9–BRG1 serial immunoprecipi-
tates (Fig. 3f). Conversely, both BRG1 and HDAC9 are captured
in VSMC lysates through the use of MALAT1 antisense probes,
but not with a control (lacZ) probe (Fig. 3g). RNA-protein
interactions prediction (RPISeq)34 conﬁrmed HDAC9 and BRG1
as highest scoring proteins interacting with MALAT1 within
HDAC9 gene association network identiﬁed above (Supplemen-
tary Fig. 3b, Supplementary Data 5).
We next examined HDAC9 and BRG1 cellular localization
during treatment of cells with MALAT1 siRNA. Surprisingly,
nuclear localization of HDAC9 is completely dependent on the
expression of MALAT1, a result not observed for BRG1 (Fig. 3h,
i, Supplementary Fig. 3f). In addition, overall HDAC9 abundance
is also reduced in siMALAT1-treated cells (Fig. 3i). Taken
together, these results suggest that silencing of MALAT1
expression may inhibit stability of the complex and therefore
may be able to prevent cellular phenotypes mediated by the
HDAC9–BRG1–MALAT1 complex. Indeed, silencing of
MALAT1 decreased the activity of MMP2 and MMP9 in VSMCs
expressing TGFR2G357W or ACTA2R179H alleles (Fig. 3j).
The HDAC9–BRG1–MALAT1 complex associates with gene
promoters. MALAT1 is known to localize to the nucleus and
shows upregulation in response to TGFR2G357W and
ACTA2R179H expression in VSMCs as well as in human TAA
tissue (Fig. 4a, Supplementary Fig. 4a). To examine the in vivo
spatial relationship between members of this putative complex,
we performed intranuclear imaging of BRG1, HDAC9, and
MALAT1 in cells expressing TGFR2G357W or ACTA2R179H
alleles. In control cells we found close association of HDAC9 with
MALAT1, whereas in cells expressing TGFR2G357W or
25kD
42kD
50kD
37kD
50kD
0
1
2
3
4
5
6
a c
b
d
0
1
2
3
37kD
20×
100×
20×
100×
20×
100×
20×
100×
Thoracic aortic aneurysm
Normal 1
Normal 1
Ao_628
Ao_628
Ao_147
Ao_147
Ao_254
Ao_254
Normal SporadicSyndromic Familial
M
as
so
n
F
-A
ct
in
/S
m
22
α
W
t
Wt
G
-a
ct
in
F
-a
ct
in
G
-a
ct
in
F
-a
ct
in
G
-a
ct
in
F
-a
ct
in
W
t AC
TA
2
R1
79
H
TG
FR
2
G3
57
W
F-actin/V5 F-actin/HDAC9
T
G
F
R
2G
35
7W
ACTA2R179H
A
C
T
A
2R
17
9H
TGFR2G357W
SM22α
SM
22
α
CN
N1
SM
TN
1
CF
L1
Cofilin1
Smoothelin
Calponin
R
el
at
iv
e 
pr
ot
ei
n 
le
ve
ls
F
-a
ct
in
/G
-a
ct
in
 r
at
io
β-actin
TGFR2G357W
ACTA2R179HWt
*
*
*
*
**
**
**
**
**
**
W
t
AC
TA
2
R1
79
H
TG
FR
2
G3
57
W
Fig. 2 TAA-related human genetic variation destabilizes the actin cytoskeleton. a Immunoﬂuorescence of VSMCs transfected with TGFR2G357W or
ACTA2R179H alleles (identiﬁed by anti-V5 staining, left column), and with anti-HDAC9 stain (red, right column), demonstrate loss of organized actin
cytoskeleton structure with anti-F-actin staining, (green, both columns). Bar= 20 µM, arrows indicate focus of 3× zoom inset panel. b Western blot
demonstrates diminishment of alpha-smooth muscle actin (α-SMA), calponin (CNN1), and smoothelin (SMTN1) expression in with TGFR2G357W or
ACTA2R179H expressing cells. Three experimental replicates are quantiﬁed. c Masson Trichrome staining of human aortic samples (top row) blue color
represents collagen deposition, and immunoﬂuorescence of human TAA samples from diverse etiologies (bottom row) demonstrates decreased F-actin
staining (green) staining with anti-SM22α (magenta, all columns) when compared to control aortic tissue. Note, F-actin staining is noted between
amorphous elastin ﬁber autoﬂuorescence. (20×, Bar= 50 µM; 63×, Bar= 15 µM). d Actin fractionation assay demonstrates decreased F-actin to G-actin
ratio in with TGFR2G357W or ACTA2R179H expressing cells. Three experimental replicates are quantiﬁed. Bar graphs are presented as mean with error bars
(±S.D.), Student’s T-test, *p < 0.05, **p < 0.01 vs. WT. Full-length western blots presented in Supplementary Fig. 8
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03394-7
4 NATURE COMMUNICATIONS |  (2018) 9:1009 | DOI: 10.1038/s41467-018-03394-7 | www.nature.com/naturecommunications
ACTA2R179H alleles, all three members, (HDAC9, BRG1, and
MALAT1) show close subnuclear colocalization (Fig. 4b).
The expression of TGFR2G357W or ACTA2R179H alleles in our
model system induced transcriptional events primarily associated
with downregulation of contractile proteins (Fig. 4c). Therefore,
we analyzed HDAC9–BRG1–MALAT1 complex binding to the
proximal promoters of genes known to be repressed in our
experimental conditions. Chromatin immunoprecipitation (ChIP
and chromatin isolation by RNA precipitation (ChiRP) assays
documented increased selective occupancy of HDAC9, BRG1,
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and MALAT1, but not other HDACs, on the promoters of
smoothelin-1 (SMTN1), calponin (CNN1), vinculin (VCL1), and
transgelin (SM22α) in the presence of TGFR2G357W and
ACTA2R179H aneurysm alleles (Fig. 4d, Supplementary Fig. 4b).
This association was closely correlated with increased promoter
histone H3K27me3 marks, a well-described marker of transcrip-
tional repression (Fig. 4d). Serial immunoprecipitation (Fig. 2f)
and immunoﬂuorescent colocalization (Fig. 4b) demonstrates an
HDAC9–BRG1–MALAT1 complex formed in cells expressing
TGFR2G357W and ACTA2R179H aneurysm alleles. To determine
whether this complex associates with relevant chromatin targets,
we performed a ChIP–reChIP experiment. This assay demon-
strates a MALAT1-dependant association of the complex with
contractile gene promoters (Fig. 4e). In keeping with this
observation, MALAT1 and HDAC9 are necessary to mediate
repression of contractile gene expression (Fig. 5a) and association
of HDAC9 with these promoters was dependent on expression of
MALAT1 and BRG1 (Fig. 5b). Unlike MALAT1 and HDAC9,
inhibition of BRG1 did not derepress contractile gene transcrip-
tion, perhaps secondary to the positive role BRG1 plays in VSMC
transcription29,30.
We next chose to visualize the subnuclear localization of
MALAT1 during genetic perturbation. In wild-type nuclei,
MALAT1 is closely associated with SC35-containing nuclear
speckles as previously described35, however in the presence of
TGFR2G357W or ACTA2R179H expression, MALAT1 staining was
redistributed from euchromatin to regions of heterochromatin
indicated by DAPI staining (Supplementary Fig. 5a&b). Con-
sistent with the role HDAC9–BRG1–MALAT1 complex in gene
repression in this context we observed colocalization of MALAT1
in subnuclear regions with increased H3K27me3 staining (Fig. 5c).
Gene silencing through H3K27me3 chromatin modiﬁcations
(Fig. 4d) is mediated by polycomb repressive complex 2 (PRC2).
Therefore, we investigated the possibility that the
HDAC9–BRG1–MALAT1 complex may recruit PRC2 to chro-
matin to mediate H3K27 methylation. Using a serial co-
immunoprecipitaion (Co-IP) approach in lysates from
TGFR2G357W or ACTA2R179H expressing VSMCs, we found that
EZH2, the catalytic subunit of PRC2, binds to the
HDAC9–BRG1–MALAT1 complex (Fig. 5d). Furthermore, ChIP
assays demonstrate that MALAT1, BRG1, and HDAC9 are
necessary for binding of EZH2 to VSMC promoters (Fig. 5e).
Targeting HDAC9–BRG1–MALAT1 improves aortic pathol-
ogy. The discovery of an epigenetic pathway induced by genetic
perturbations mediating deleterious VSMC phenotypes prompted
consideration of modulating this pathway for therapeutic beneﬁt.
Initially, we chose to examine for co-association of the members
of the HDAC9–BRG1–MALAT1 complex in cells from
Fbn1C1039G/+ (Marfan) mice, a validated and widely-used model
of hereditary aortic disease. Using confocal microscopy, similar to
observations in VSMCs expressing TGFR2G357W or ACTA2R179H
alleles, VSMCs explanted from the aortas of Fbn1C1039G/+ mice
show increased colocalization of Malat1, Brg1, and Hdac9 when
compared to wild-type mice (Fig. 6a). Similarly, we found
increased expression of Hdac9, Brg1, and Malat1 transcripts and
colocalization between members of the complex in Fbn1C1039G/+
mice but not in aortas of wild-type littermates (Fig. 6b, c).
We next examined the effect of inhibition of complex
formation in Fbn1C1039G/+ (Marfan) mice by crossing them to
Malat1-deﬁcient (Malat1−/−) and VSMC targeted Hdac9-deﬁ-
cient animals (Hdac9ﬂ/ﬂ:Tagln-cre) (Supplementary Fig. 6a-c)36.
Fbn1C1039G/+:Malat1−/− and Fbn1C1039G/+:Hdac9ﬂ/ﬂ:Tagln-cre
mice demonstrated normal blood pressure (Supplementary
Fig. 6d). As assessed by ultrasound, both Fbn1C1039G/+:Malat1
−/− and Fbn1C1039G/+:Hdac9ﬂ/ﬂ:Tagln-cre mice demonstrated
smaller ascending aortic dimensions when compared to
Fbn1C1039G/+ mice, while the aortic dimensions of Malat1−/−
and Hdac9ﬂ/ﬂ:Tagln-cre mice were indistinguishable from wild-
type littermates (Fig. 6d, Supplementary Data 6). The ascending
aortas of Fbn1C1039G/+ mice demonstrated elastin fragmentation
with VSMC proliferation and disarray37,38, a phenotype
improved by Malat1 or Hdac9 deletion (Fig. 6e). In a
corresponding fashion, organized F-actin staining was lost in
Fbn1C1039G/+ aortas, but restored by Malat1 or Hdac9 deletion
(Fig. 6e, Supplementary Fig. 6e). Aortic disease in experimental
animals and humans has been associated with increased
activation of the TGF-β signaling cascade as assayed by increased
phosphorylation of Smad2 and ERK38,39. When compared to
Fbn1C1039G/+ mice, phosphorylation of both Smad2 and ERK
were decreased in the aortas of Fbn1C1039G/+:Malat1−/− mice
and Hdac9ﬂ/ﬂ:Tagln-cre (Supplementary Fig. 6f&g). Previously we
demonstrated decreased MMP activation in our cellular models
of aneurysm after silencing of the MALAT1 expression (Fig. 2j).
Similarly, in vivo MMP activity in the ascending aortas of
Fbn1C1039G/+:Malat1−/− or Fbn1C1039G/+:Hdac9ﬂ/ﬂ:Tagln-cre
mice mice was decreased when compared to Fbn1C1039G/+ mice
(Fig. 7a). Immunolocalization of MMP2 and MMP9 isoforms
within experimental aortas suggests that medial VSMCs are the
source of MMP production (Supplementary Fig. 7a&b).
We next undertook qPCR analysis of described markers of
VSMC phenotypic state from the aortas of experimental mice.
Genetic deletion ofMalat1 or Hdac9 largely restored “contractile”
Fig. 3 HDAC9 interacts with BRG1 and the lncRNA, MALAT1. a Increased expression of HDAC9 protein is noted in TGFR2G357W or ACTA2R179H
expressing alleles by western blot when compared to other HDAC isoforms in human VSMCs. Three experimental replicates are quantiﬁed. b
Immunoprecipitation of BRG1 demonstrates HDAC9 binding in TGFR2G357W and ACTA2R179H expressing mutant cells. Quantiﬁcation of protein levels of
three replicate experiments. c Top, CLIP-seq analysis of anti-HDAC9 and anti-BRG1 immune complexes illustrated by Venn diagram showing the number of
transcripts detected by puriﬁcation with both antibodies at baseline or during expression of TGFR2G357W or ACTA2R179H alleles. Bottom, cellular function
of 107 core transcripts by ingenuity pathway analysis. d Quantitative PCR analysis of known cardiovascular lncRNAs during the expression of TGFR2G357W
or ACTA2R179H alleles. e Quantitative PCR analysis of cardiovascular lncRNAs associated with either anti-HDAC9 or anti-BRG1 immune complexes. Four
experimental replicates are quantiﬁed. f Serial immunoprecipitation of BRG1 and HDAC9 demonstrates the association of the lncRNA MALAT1 with BRG1-
HDAC9 immunocomplexes. Quantiﬁcation of protein levels of three replicate experiments. g Western blot analysis of HDAC9 and BRG1 proteins captured
through UV crosslinking of bead immobilized biotinylated MALAT1 or LacZ antisense RNA probes. Three replicates are quantiﬁed. h Immunoﬂuorescence
of HDAC9 and BRG1 demonstrate lack of nuclear localization of HDAC9 in siMALAT1-treated cells. Bar= 15 µM, circles indicate nuclei location in
siMALAT-treated cells, arrows indicate apparent cytoplasmic HDAC9 aggregates. i Semiquantitative western blot analysis of HDAC9 and HDAC1 from
nuclear extracts (NE) and cytoplasmic extracts (CE) from control and siMALAT1-treated VSMCs. j siMALAT1 treatment of VSMCs decreases
TGFR2G357W or ACTA2R179H mediated induction of MMP activity by in vitro gelatin zymography. Bar graphs are presented as mean with error bars (±S.
D.), Student’s T-test, *p < 0.05, **p < 0.01 vs. WT. Full-length western blots presented in Supplementary Fig. 8
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transcript levels from Fbn1C1039G/+ mice while having no large
effect on the expression of “synthetic” markers (Fig. 7b,
Supplementary Fig. 6g). Consistent with this, we detected
increased H3K27me3 modiﬁcations at the Tagln promoter in
Fbn1C1039G/+ aortas vs. wild-type aortas, while Malat1 or Hdac9
deletion restored wild-type levels of this repressive modiﬁcation
(Fig. 7c). Molecular analysis of Malat1 and Hdac9-deﬁcient
Fbn1C1039G/+ aortas demonstrated recovery of expression of
many extracellullar matrix proteins, including members of the
contractile protein apparatus whose levels decreased in
Fbn1C1039G/+ mice vs. wild type including restoration of
calponin, smoothelin, and Sm22α contractile protein expression
(Fig. 7d). Conversely, Fbn1C1039G/+ induced coﬁlin upregulation
was reversed by Hdac9 or Malat1 deﬁciency (Supplementary
Fig. 7b).
Discussion
Although often explored in developmental contexts, epigenetic
reprogramming is an emerging theme in homeostatic control of
differentiated cell types. Large-scale transcriptional changes
driving phenotypic events often involve the coordinated action of
nucleoprotein complexes that have adaptable function depending
on cellular and tissue type requirements. In this study, we
demonstrate that the HDAC9–BRG1–MALAT1 complex repre-
sents one such complex involved in pathologic reprogramming of
VSMCs (Fig. 8).
Human sequence variants at the HDAC9 locus have been
associated with vascular diseases such as large vessel ischemic
stroke19, myocardial infarction20, intracranial aneurysm18, and
aortic calciﬁcation (R. Malhotra, personal communication).
HDAC9 appears to be the disease relevant gene at this locus based
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on expression studies40, arguing strongly for the importance of
this factor in vascular cellular performance. However, the
mechanism by which HDAC9 mediates vascular disease is not
clear. Experimental data in rodents implicates augmented
HDAC9 activity in multiple tissue types including adipocytes and
macrophage. For instance, in experimental atherosclerotic disease
HDAC9 has been shown to play a directive role in the modula-
tion of cholesterol efﬂux and the generation of alternatively
activated macrophages41. In the adipocytic lineage, Hdac9
downregulation is required for differentiation of preadipocytes
into mature adipocytes, and knockdown of Hdac9 prevents
metabolic dysregulation in high-fat feeding42,43. However,
genetically triggered TAA is a noninﬂammatory and non-
atherogenic process, and human genetic perturbations that cause
TAA clearly implicate dysfunction of VSMCs44. The data pre-
sented here indicate a novel VSMC-speciﬁc function for HDAC9
from those previously implicated in cardiovascular disease.
Indeed, considering its wide and variable expression within the
vascular system, mechanistic interpretation of human HDAC9
genetic associations that implicate a single cell type or even a
single pathologic process may be simplistic.
Genetic mutations that disrupt cytoskeletal architecture induce
both HDAC9 expression and the formation of the
HDAC9–BRG1–MALAT1 complex. We speculate that disruption
of the actin cytoskeleton mediates the lack of wound healing
function with increased MMP activity seen in our assays (Fig. 1f,
g, Supplementary Fig. 1a), uncommon behavior for VSMCs
where increased mobility is typically coupled with MMP upre-
gulation. The mechanism by which actin destabilization signals
formation of the nuclear complex is unclear. One candidate
would be an increased concentration of monomeric beta-actin
itself, which has been repeatedly found bound within BRG1-
containing complexes45. However, we could not detect direct
beta-actin binding to the HDAC9–BRG1–MALAT1 complex, and
therefore such a mechanism remains speculative. Nuclear locali-
zation of HDAC9 appears to be dependent on MALAT1
expression. We hypothesize that MALAT1 may either directly
regulate HDAC9 phosphorylation or more likely exclude binding
of HDAC9 to 14-3-3 proteins, known to be involved in cyto-
plasmic retention of class II HDACs46. It is formally possible that
increased nuclear concentrations of HDAC9 and MALAT1 are
sufﬁcient to initiate formation of the HDAC9–BRG1–MALAT1
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Fig. 5 HDAC9–MALAT1–BRG11 is required for EZH2 recruitment to chromatin. a Qualitative PCR analysis of synthetic and contractile genes demonstrate
HDAC9 and MALAT1-dependant repression in TGFR2G357W or ACTA2R179H expressing VSMCs. b HDAC9 chromatin immunoprecipitation assays (ChIP)
demonstrates MALAT1 and BRG1-dependant association with VSMC promoters. c MALAT1 ﬂuorescence in situ hybridization (FISH) shows colocalization
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ectopically expressed EZH2 demonstrating association with sequential BRG1 and HDAC9 immunoprecipitates in TGFR2G357W or ACTA2R179H expressing
cells. e Chromatin immunoprecipitation assays (ChIP) demonstrate HDAC9, BRG1, and MALAT1-dependant association of EZH2 with VSMC promoters.
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**p < 0.01 vs. WT. Full-length western blots presented in Supplementary Fig. 8
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03394-7
8 NATURE COMMUNICATIONS |  (2018) 9:1009 | DOI: 10.1038/s41467-018-03394-7 | www.nature.com/naturecommunications
complex, indeed the expression of these two factors is coreguated
as evidenced by decreased HDAC9 levels after suppression of
MALAT1 through siRNA silencing (Fig. 3i). While concentration
dependent assembly may dictate complex formation, it seems
probable that signal-mediated assembly mechanisms may also be
elucidated. We do observe the complex associating with the
promoters of cytoskeletal genes and with repressive chromatin
marks within nuclear regions with repressive character in
response to actin destabilization. These ﬁndings are consistent
with the previous implication of HDAC9 in the repressive control
of transcriptional programs47. It should be noted that although
the majority of studies have documented downregulation of
contractile protein elements in TAA48–51, at least one study has
seen upregulation52, demonstrating that protein expression con-
trol mechanisms within TAA subtypes may be more diverse than
suspected. The catalytic domain of HDAC9 has been shown to be
dispensable for its role in adipogenesis, and indeed we that found
abnormal VSMC phenotypes could be induced through over-
expression of MITR, an HDAC9 isoform lacking its catalytic
domain. Therefore, the role of HDAC9 in the complex may
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Fig. 6 Genetic disruption of Malat1 or Hdac9 improves experimental aortic aneurysm. a Explanted VSMCs from Fbn1C1039G/+ mouse aortas demonstrate
increased colocalization of Hdac9–Brg1 as well as Malat1–Brg1 when compared to wild-type cells. Global Pearson’s colocalization (GPC) of spatial overlap
between Hdac9–Brg1 and Malat1–Brg1 is shown. Bar= 2.5 µM b Identiﬁcation of Hdac9–Malat1–Brg1 complex in wild type and Fbn1C1039G/+ by confocal
microscopy of ascending aortic samples. Bar= 40 µM c QPCR of Hdac9, Malat1, and Brg1 demonstrate upregulation in Fbn1C1039G/+ aortas, bar graphs are
presented as mean with error bars (±S.D.) n= 6 animals, 6 months of age (d) Improved quantitative aortic dimensions in Fbn1C1039G/+:Malat1−/− and
Fbn1C1039G/+:Hdac9ﬂ/ﬂ:Tagln-cre mice when compared to Fbn1C1039G/+ mice. Ultrasound of aortic root (Red) and ascending aortic (Black) quantiﬁcation of
wild-type (n= 18), Malat1−/− (n= 18), Hdac9ﬂ/ﬂ:Tagln-cre (n= 17), Fbn1C1039G/+ (n= 24), Fbn1C1039G/+:Malat1−/− (n= 19), and Fbn1C1039G/+:Hdac9ﬂ/ﬂ:
Tagln-cre (n= 15; One-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001). Aortic dimensions at 6 months and aortic growth between 16 and 24 weeks are
shown. Representative images of parasternal long axis systolic ultrasound images of the aortic root of 6-month old mice. Red arrows denote aortic root,
white arrows denote ascending aorta. Bar= 1 mm (e) Malat1 and Hdac9 deﬁciency rescues anatomic and cytoskeletal defects in Fbn1C1039G/+ aortas.
Representative photomicrographs of six month old latex-injected wild-type, Malat1−/−, Hdac9ﬂ/ﬂ:Tagln-cre, Fbn1C1039G/+, Fbn1C1039G/+:Malat1−/−, and
Fbn1C1039G/+:Hdac9ﬂ/ﬂ:Tagln-cre hearts and ascending aortas (left column, Bar= 1 mm, middle and right column, Bar= 40 µM). Red arrows indicate the
ascending portion of the aorta. Aortas stained with Verhoeff-Van Gieson stain (center panels), and immunoﬂuorescence of F-actin (right panels). The
aortic adventitia faces left while the aortic lumen is oriented to the right. Quantiﬁcation of aortic architecture and F-actin staining, (One-way ANOVA, *p <
0.05, **p < 0.01, ***p < 0.001). Full-length western blots presented in Supplementary Fig. 8
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primarily be the recruitment of other chromatin modifying fac-
tors, such as PRC2, to sequence-speciﬁc chromatin binding sites
through interaction with MEF2 or other transcription factors53,54.
The other member of the complex, MALAT1, is a well known
constituent of SC35-containing nuclear speckles, nuclear domains
rich in pre-mRNA splicing factors55. Indeed, as seen in most cell
types, colocalization of MALAT1 with SC35 and euchromatin are
noted in VSMCs at rest (Supplementary Fig. 5a). However, in the
presence of aneurysm-associated alleles MALAT1 is more closely
associated with heterochromatin and regions of dense H3K27
trimethylation (Fig. 5c). These data imply a repressive rather than
facilitative role for MALAT1 in gene expression in this context, in
contrast to observations in healthy cells56. This type of func-
tionality has however been previously observed in MALAT1
biology, in fact, the 3’ end of MALAT1 has been described to bind
directly to and recruit EZH2, the catalytic subunit of the PRC2
complex to mediate silencing of target genes57,58. Deletion of
MALAT1 or treatment with antisense oligonucleotides targeting
MALAT1 has been shown to promote differentiation of
mammary tumors and prevent metastasis in experimental mice59.
Gene expression changes in these cells were noted to be diverse
and both activation and repression of gene sets were noted in
RNA-seq experiments59. Although we have studied repressive
events in this study, it is quite plausible that activating tran-
scriptional events and modulation of splicing events mediate
equally important phenotypes and inhibition of these events by
MALAT1 deﬁciency may motivate improvements in VSMC
performance. In fact, considering the commonalities observed
between cancer cells and synthetic VSMCs (increased MMP
expression, cytoskeletal instability, etc.), the ability of MALAT1
depletion to induce a differentiated phenotype may prove a
generalized strategy to improve cellular performance in multiple
conditions associated with cellular dedifferentiation.
Recently, an HDAC-BRG1 complex was implicated in stress
responsive gene repression in experimental cardiac hypertrophy,
possibly an analogous complex operating within cardiomyo-
cytes27,31. Indeed, we demonstrated contractile promoter occu-
pancy of other HDAC isoforms, (HDAC1, HDAC2, and HDAC3)
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error bars (±SD). Full-length western blots presented in Supplementary Fig. 9
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under our experimental conditions (Supplementary Fig. 4b),
albeit not consistently. In cardiomyocytes, the HDAC9–BRG1
complex was shown to be inhibited by the lincRNA Mhrt, which
prevents its association with chromatin by competitive binding at
the helicase domain of BRG1. In contrast, the lincRNA MANTIS
has been shown to facilitate BRG1 function in endothelial
lineages60,61. In our study, the lncRNA MALAT1 is required for
proper association between BRG1 and HDAC9, and depletion of
MALAT1 inhibits both stable formation of the complex and the
nuclear localization of HDAC9. These data illustrate how reg-
ulatory RNAs can work as both positive and negative modulators
of transcription in differentiated cell types. As expected from its
location within the Myh7 locus, Mhrt was not
expressed in VSMCs (Fig. 3d) and it remains to be seen if
smooth muscle lineages have evolved a speciﬁc lincRNA to
antagonize BRG1-chromatin interactions.
HDAC9 has been associated with multiple human vascular
diseases including hypertension, stroke19, aneurysm18, and
myocardial infarction20 amongst others. The mechanistic
underpinnings of this genetic association is unclear, however
VSMC dysfunction is believed to be fundamentally related to the
pathogenesis of each of these vascular disorders. The elucidation
of a novel HDAC9-containing complex mediating transcriptional
dysregulation in VMSCs may open new avenues for therapeutic
intervention for these important human diseases.
Methods
Aortic Samples. Aortic samples were collected from patients undergoing cardiac
surgery at the Massachusetts General Hospital (MGH). Demographics of thoracic
aortic aneurysm patients are listed in Supplementary Table 2. Control aortic tissue
was obtained from patients undergoing orthotopic cardiac transplant. IRB per-
missions do not allow for demographic information from discarded tissue to be
collected or stored. All tissue samples were collected in compliance with the
Partners Healthcare Institutional Review Board (IRB) requiring written informed
consent.
Aortic smooth muscle cell lines. Primary human aortic smooth muscle cells
(VSMC) from healthy donors were purchased from Cell Applications Inc. (354K-
05a), California, USA. In order to preserve cell identity all experiments were carried
out at passages 1–562. Primary VSMC from wild-type and Hdac9−/− mice were
isolated from the proximal ascending section of aortas by standard explant pro-
tocol. Smooth muscle cell identity was assessed by immunoﬂuorescence staining of
contractile markers including Sm22α (Abcam, ab14106), Calponin1 (Abcam,
ab46794), Smoothelin1 (Santa Cruz, sc-73042), and Vinculin1 (Abcam, ab18058).
siRNA inhibition, wound healing and microarrays. Human aortic smooth muscle
cells (HAoSMC) were acquired from Cell applications, Inc. (354K-05a) and seeded
into silicone inserts plates with a deﬁned cell-free gap (Ibidi-labware) and trans-
fected 24hrs with speciﬁc siRNA against SMAD3, TGFB2, ACTA2 and MYH11.
After 24 h silicone inserts were removed to generate the initial wound. No anti-
proliferative agents were added to the media, therefore wound healing in our assay
reﬂects the combined activity of migration and proliferation. The wound healing/
closure was evaluated 24 and 48hrs later. Validation of the gene silencing was
performed by qRT–PCR and immunoblotting for each targeted gene (Supple-
mentary Fig. 1g). Total RNA was extracted from HAoSMC transfected with
siRNA-negative control, siSMAD3 and siACTA2 using miRNeasy kit (Qiagen)
following the manufacturer’s protocol. RNA samples were used to hybridize Agi-
lent gene expression microarrays (v2. mRNA microarrays, Agilent). Brieﬂy, 100 ng
of total RNA was used as the starting template for cDNA synthesis. This cDNA was
used as a template to synthesize Cy3-labeled cRNA that was hybridized on 8 × 60 K
high density SurePrint G3 gene expression human Agilent microarrays at 65 °C for
17 h. All arrays were normalized by cyclic-LOESS and signiﬁcance analysis of
microarrays (SAM) was applied for statistical analysis of the differentially
expressed genes setting a 5% false discovery rate as a cutoff of statistical sig-
niﬁcance. 44 genes were found to be dysregulated in the same direction for both
siRNA conditions compared with the control group. Fourteen genes were ran-
domly chosen to be validated by qRT–PCR. RNA samples were used to run
qRT–PCR on SYBR green system (Applied Biosystem, Foster city, CA). Results
were analyzed by the ddCT method and GAPDH (encoding glyceraldehyde-3-
phosphate dehydrogenase) was used as a housekeeping gene. Fold change were
calculated by taking the average over all the control samples as the baseline.
Network analysis. Ingenuity Pathway Analysis (IPA, Ingenuity Systems) software
was used to identify potential networks and canonical pathways associated with the
commonly dysregulated genes; all 44 differentially expressed genes were included
in the analysis. The predicted activation state and activation Z-score are based on
the direction of fold change values for those genes in the input data set for which
an experimentally observed causal relationship has been established.
Production of aneurysm alleles in vitro. Human wild-type cDNAs of TGFBR2
and ACTA2 were separately cloned into a lentivirus plasmid containing a V5
epitope tag and an Emerald Green Fluorescent Protein (EmGFP). Point mutations
for TGFR2G357W and ACTA2R179H were introduced with primers (Supplementary
Data 7) for site-directed mutagenesis by PCR designed basically according to the
manufacture (QuikChange™ Mutagenesis kit; Agilent Technologies, CA). Viruses
were produced using the ViraPower lentiviral expression system (Invitrogen)
according to the manufacturer’s protocol. After 96 h of viral infection, cells
expressing wild-type or mutant proteins were detected using ﬂuorescent micro-
scopy (FITC) or Blasticidin selection. RNA and protein levels were analyzed 48hrs
after viral expression. Cell viability was assessed using CellTiter-Glo® 2.0 Assay
(Promega) according to the manufacturer’s instruction. Determination of pro-
liferation proﬁle in wild-type or TGFR2G357W and ACTA2R179H mutant cells was
measured by immunoﬂuorescence detection of Ki67 and PCNA.
Actin cytoskeleton disruption assay. Human VSMCs were treated with Phal-
loidin (1 µM) or Latrunculin A (1 µM) for 40 min before preparation of nuclear
protein extracts and analyzed by SDS–PAGE/western blot. For living cell micro-
scopy, human HDAC9/MITR cDNA lacking the HDAC catalytic domain were
cloned into a lentivirus plasmid encoding the tdTomato ﬂuorescent protein tag
from Takara Bio USA, company (pLVX-tdTomato-N1). Then human VSMCs were
transduced with virus particles overexpressing tdTomato-HDAC9 followed by
treatment with Latrunculin A (1–3 µM) for 40 min using Leica TCS SP8 micro-
scopy station.
Immunoblotting and immunoprecipitation. All uncropped western blots are
presented in Supplementary Figs. 8&9. All antibodies used in the study are sum-
marized in Supplementary Data 7. Nuclear and cytoplasmic protein lysates were
prepared using NE-PER Kit (Pierce, Rockford, IL, USA) and supplemented with 1×
of protease inhibitor cocktail (Roche) according to the manufacturer’s instruction.
For detection of nuclear proteins 20 µg of total nuclear extracts were mixed with
denaturing buffer (1× Laemmli loading buffer with 10% of β-mercaptoethanol) and
analyzed by SDS–PAGE/western blot. Separated proteins were transferred onto a
nitrocellulose membrane using the iBlot transfer system (Novex, ThermoFisher,
USA). For detection of cytoplasmic proteins 15 µg of cytoplasmic extracts were
mixed with denaturing buffer as described above. In general, primary antibodies
were used at concentration of 1:100 and secondary at concentration of 1:10000,
although speciﬁc concentrations are listed in Supplementary Data 7. For co-
immunoprecipitation assays 40 µg of nuclear extracts were incubated with primary
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Fig. 8 Disease induced transcriptional repression by the
HDAC9–BRG1–MALAT1 complex. a In the healthy aorta, genes responsible
for normal aortic homeostasis are transcribed by multiple transcription
factors (TF) such as MEF2, Myocardin, and Myocardin-related transcription
factors (MRTFs). b Disease processes activate assembly of the
HDAC9–BRG1–MALAT1 complex. The promoters of target genes are
silenced through the action of the complex and the acquisition of histone 3
lysine 27 trimethylation through polycomb repressive complex 2 (PRC2). c
Reduced dosage of MALAT1 and/or HDAC9 causes destabilization of the
complex and allows for expression of silenced gene loci and reversal of
deleterious phenotypes
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antibody (5 µg) overnight at 4 C followed by co-immunoprecipitation using Pierce
Co-IP kit (Thermo Scientiﬁc) according to the manufacturer’s instructions. Then
lysates were incubated with A/G magnetic beads for 2hrs at 4 C and washed three
times with IP buffer (Santa Cruz biotechnologies, USA). Eluate was boiled in
denaturing buffer for 10 min at 100 C and analyzed by SDS–PAGE/western blot.
For sequential Co-IP 200 µg of nuclear extracts were supplemented with RNAse
inhibitor (1:100), protease inhibitor cocktail, phenylmethylsulfonyl ﬂuoride (1 mM,
PMSF) and treated with turbo DNAse I for 30 min at 37 C. Then lysates were
incubated with 5 µg of BRG1 (Abcam, ab110641) antibody overnight at 4 C on a
rotator. Next samples were incubated with A/G agarose beads for 2 h at 4 C on a
rotator followed by 3× washes with lysis buffer using centrifugation to pull-down
agarose beads. Then samples were resuspended in 1 mL of dilution buffer.
Meanwhile 5 µg of HDAC9 (Abcam, ab59718) antibody per sample was biotiny-
lated using Biotin (Type B) Fast Conjugation Kit (Abcam, ab201796). Resuspended
samples were then incubated with 5 µg of Biotinylated-HDAC9 antibody for 4 h at
4 C on a rotator followed by incubation with magnetic streptavidin beads for 2 h at
4 C on a rotator. Beads were 3× washed and boiled in denaturing buffer for 10 min
at 100 C and analyzed by SDS–PAGE/western blot. For F-actin/G-actin ratio
determination cells were treated with Lysis and F-actin stabilization buffer from G-
Actin/F-actin. In Vivo Assay Biochem Kit and according to the manufacturer’s
instruction (Cytoskeleton, Inc., USA). Brieﬂy 30 µg of stabilized lysates were ﬁrst
centrifuge at 350 × g for 5 min to remove cellular debris. Then supernatants were
ultra centrifuged at 100000×g for 1 h. After centrifugation G-actin was collected
from the supernatants and F-actin was collected from the pellets. Equal volumes
(25 µL) from each fraction were analyzed by SDS–PAGE/western blot analysis as
above. For protein analysis in animals, the ascending sections of the aorta were
used to prepare total protein extracts using T-PER tissue protein extraction buffer
(Thermo scientiﬁc) followed by 2 × 5min of mechanic homogenization using
TissueLyser LT (Qiagen, USA). 20 µg of total protein per sample were used. The
Odyssey infrared western system was used to detect target proteins. Band intensity
was quantiﬁed using ImageJ software. Uncropped scans of all the blots presented in
the manuscript are shown in Supplementary Fig. 5a&b.
Protein precipitation by MALAT1 isolation. 10 million cells of either wild type or
aneurysm mutant cells were UV cross-linked using 2000 µJoules/cm2 followed by
extraction of nuclear protein using NE-PER Kit (Pierce, Rockford, IL, USA) and as
previously described63. Brieﬂy 50 µg of UV cross-linked nuclear lysates were
supplemented with RNAse inhibitor (1:100), protease inhibitor cocktail (1 × ),
phenylmethylsulfonyl ﬂuoride (1 mM, PMSF) and treated with turbo DNAse I
(Ambion, ThermoFisher, USA) for 30 min at 37 C. Nuclear lysates were mixed with
biotinylated DNA probes targeting MALAT1 or LacZ and incubated at 55 C for 3
h. before overnight incubation with yeast RNA-blocked streptavidin magnetic
beads at 37 C. Beads were washed three times and retreated with turbo DNAse I for
10 min at 37 C. Beads were washed three more times and incubated with 20 µl of
denaturing buffer at 100 C for 10 min followed by SDS–PAGE/western blot
analysis.
MMP activity. For in vitro MMP activity, VSMCs expressing wild type or
TGFR2G357W and ACTA2R179H were co-transfected with 30 nM of siCTRL or
siHDAC9 for 48hrs as described above. After 24hrs of growing medium 30 µg of
total protein were prepared from siCTRL and siHDAC9 treated cells to measure
the MMP activity by gelatin zymography59. 3D plot was generated using ImageJ
software. For in vivo MMP activity assay, mice were tail vein injected with 600uL of
MMPSense 750 FAST, a near-infrared ﬂuorescence sensor for MMP2 and MMP9
activity, (PerkinElmer, USA). Mice were killed 24 h post injection and aortas were
dissected and analyzed using a Kodak image station 4000MM Pro for macroscopic
ﬂuorescence reﬂectance molecular imaging64.
Sequential FISH and immunoﬂuorescence microscopy. Stellaris® FISH Probes
recognizing human MALAT1 (SMF-2035-1) or mouse Malat1 (SMF-3008-1) and
labeled with Quasar® 570-labeled oligos (Biosearch Technologies, Inc., Petaluma,
CA) were hybridized to VSMCs or tissue samples, followed by incubation with
primary and secondary antibodies following the manufacturer’s instructions
available online at www.biosearchtech.com/stellarisprotocols. Imaging and analysis
were performed using Volocity 5.2 software. Three-dimensional and quantitative
ﬂuorescence co-localization analysis were performed as described previously65.
Two-dimensional and white light images were analyzed using ImageJ software.
ChIP–qPCR, ChIP–reChIP and ChiRP. For ChIP–qPCR 10 million cells were used
from wild type, TGFR2G357W and ACTA2R179H and were ﬁxed with 1% of for-
maldehyde at 37 C for 20 min, quenched with 125 mM glycine for 5 min (RT) and
protein lysates were prepared using EpiTect ChIP kit according to the manu-
facturer’s instructions (Qiagen, USA). For ChIP–qPCR from mouse aortas 30 mg of
fresh tissue corresponding to the ascending region was ﬁxed with 1% of for-
maldehyde at 37 C for 30 min, quenched with 125 mM glycine for 5 min (RT) and
protein lysates were prepared as described above. ChIP-ed DNA was used to
analyze the promoter occupancy of contractile genes by qPCR. For ChIP–reChIP66,
wild type, TGFR2G357W and ACTA2R179H were transfected with siCTRL or
siMALAT1 as described above. Then 50 million cells from either siCTRL or
siMALAT1-treated cells were ﬁxed with 1% of formaldehyde at 37 C for 20 min
quenched with 125 mM glycine for 5 min (RT). Then protein lysates were sup-
plemented with 1× of protease inhibitor cocktail (Roche), RNAse inhibitor (1:50)
and 1 mM PMSF and incubated on ice for 15 min. Next lysates were sonicated to
shear chromatin to an average length of 500-1500 bp followed by centrifugation for
10 min at max speed. Supernatants were collected in 2 mL tube containing 6 µg of
BRG1 (Abcam, ab110641) antibody and 1 mL of lysis buffer supplemented with 1×
of protease inhibitor cocktail (Roche), RNAse inhibitor (1:50) and 1 mM PMSF and
incubated overnight (14 h) at 4 C. Next samples were incubated with A/G agarose
beads for 1 h at 4 C on a rotator followed by 3× washes with lyses buffer using
centrifugation to pull-down agarose beads. Then samples were resuspended in 1
mL of dilution buffer as described previously. Meanwhile 6 µg of HDAC9 (Abcam,
ab59718) antibody per sample was biotinylated using Biotin (Type B) Fast Con-
jugation Kit (Abcam, ab201796). Resuspended samples were then incubated with 6
µg of Biotinylated-HDAC9 antibody for 4 h at 4 C on a rotator followed by
incubation with magnetic streptavidin beads for 1 h at 4 C on a rotator. Beads were
3× washed and ChIP-ed DNA was prepared using EpiTect ChIP kit as described
above. We carried out ChIRP assays as described by Chu and collaborators, 201267.
Brieﬂy 50 million cells were used from wild type, TGFR2G357W and ACTA2R179H
and cross-linked with 1% glutaraldehyde for 20 min at RT. Then cells were harvest
in lysis buffer supplemented with 1× of protease inhibitor cocktail (Roche), RNAse
inhibitor (1:50) and 1 mM PMSF followed by sonication as described previously.
Next resuspended chromatin was incubated with biotinylated probes recognizing
MALAT1 or LacZ (negative control) transcripts for 4hrs on a rotator followed by
incubation with magnetic streptavidin beads (100 µL) for 1 h at RT. RNA and DNA
isolations were performed as described67. QPCR was used to analysis signals in
input and immunoprecipitates. The percentage of immunoprecipitates signals was
calculated over the input signals. Experiments were performed in triplicates, with
independent samples. Promoter locus of cardiac troponin 3 (cTNN3) was used as
negative control in the ChIP experiments. Primers used for the qPCR are listed in
Supplementary Data 7.
CLIP-seq. For CLIP-seq 100 million cells were UV cross-linked using 2000 µJoules/
cm2 followed by extraction of nuclear proteins. UV cross-linked lysates from wild-
type, TGFR2G357W and ACTA2R179H cells were pre-supplemented with RNAse
inhibitor (1:50), protease inhibitor cocktail, phenylmethylsulfonyl ﬂuoride (1 mM,
PMSF) and treated with turbo DNAse I for 30 min at 37 C. Lysates were then
incubated with 5 µg of HDAC9 or BRG1 antibodies at 4 C overnight. RNA
extraction from HDAC9 and BRG1 pull downs were performed using miRNeasy
kit (Qiagen, USA) according to the manufacturer’s instruction. RNA sequencing
for human mRNA and lncRNAs were performed using Ribo-Zero™ Magnetic Kit
and RnaseH is used to remove rRNA, remained RNA is then retrieved by ethonal
precipitation. The retrieved RNA is fragmented using Ambion Fragmentation
Solution. And according to Illumina solexa transcriptome sequencing protocol,
random hexamer-primer was used to synthesize the ﬁrst-strand cDNA. The
second-strand cDNA is synthesized using buffer, dNTPs, RNaseH and DNA
polymerase I. Fragments are puriﬁed with QiaQuick PCR extraction kit and
resolved with EB buffer for end reparation and adding A at 3’ end. After that, the
fragments are ligated with sequencing adaptors. UNG is added before synthesizing
the second cDNA strand. After the second strand degraded, dUTP is then con-
verted to dTTP. Y-adaptor is added afterwards. Suitable fragments are selected as
templates according to the agarose gel electrophoresis results for PCR ampliﬁca-
tion. Generated libraries were sequenced using Illumina HiSeq™ technology. CLIP-
seq reads were aligned to human UCSC h19 using standard Illumina library-type.
Cufﬂinks 2.0.2 was run on merged bam ﬁles to assemble of transcripts and esti-
mation of FPKM values. FPKM ≤ 1.0 cutoff was used as detection threshold to
generate the list of genes. For coverage of MALAT1 transcript the fastqs ﬁles were
aligned to the human genome (hg19) using STAR68. Bedtools CoverageBed (v2.26
http://bedtools.readthedocs.io/en/latest/content/tools/coverage.html) is used for
each of the sorted (by chromosome position) alignment bam ﬁles to obtain the red
coverage for each base in the MALAT1 gene region. The BED ﬁle for MALAT1 was
obtained from ENSEMBL 75 for the canonical transcript that has a length of 8708
bases. The read coverage for each sample is then normalized to reads per million
mapped to the human genome (RPM) by considering only the reads that map
uniquely to the human genome respectively. Genomic data from CLIP-seq
experiments was deposited to GEO under the access number GSE41607.
Mice. All mice were cared for under strict compliance with the Partners Institu-
tional Animal Care and Use Committee (IACUC), regulated by the United States
Public Health Service (USPHS) and the United States Department of Agriculture
(USDA). Malat1 knockout mice were kindly provided by Dr. David Spector36.
Hdac9 knockout aortic VSMCs were derived from mice kindly provided by Dr. Eric
Olson47. Hdac9ﬂox/ﬂox were generated and kindly provided by Dr. Neal Weintraub.
Tagln-cre mice were acquired from Jackson laboratories (B6.Cg-Tg(Tagln-cre)
1Her/J, # 017491)69 Marfan (Fbn1C1039G/+) mice were acquired from Jackson
laboratories (B6.129-Fbn1tm1Hcd/J, #01885)37. For tissue analysis, animals were
euthanized through inhalational isoﬂurane (Sigma, St, Louis, MO) prior to tissue
collection. Age and sex of all animals used in the study are described in Supple-
mentary Data 6. All tissue experiments were performed after sacriﬁce at 6 months
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03394-7
12 NATURE COMMUNICATIONS |  (2018) 9:1009 | DOI: 10.1038/s41467-018-03394-7 | www.nature.com/naturecommunications
of age unless described differently. All experiments were performed on male and
female animals at a 1:1 ratio.
Ultrasounds. Nair hair removal cream was used on all mice the day prior to
ultrasounds. All ultrasounds were performed on awake, unsedated mice using the
Visualsonics Vevo660 imaging system and a 30MHz transducer. The aorta was
imaged using a standard parasternal long axis view. Dimensions from each animal
represent averages of measurements made on still frames in systole of the maximal
internal diameter of the aortic valve annulus, aortic sinuses, sinotubular junction,
or ascending aorta by a cardiologist blinded to genotype. On the basis of historic
controls, the mean diameter of the wild-type aorta at 6 months of life is 1.75+ /-
0.2 mm while in our disease model (Fbn1C1039G/+) the mean diameter is 2.2 ± 0.3
mm. We calculated a need for ~10 animals per group at a power (1-β) of 0.8 and a
Type I error rate (α) of 5% to detect a 0.34 mm (57%) mean improvement (vs. 2.2
mm mean) improvement in aneurysm diameter.
Histology. Latex was injected into the left ventricular apex under low pressure
until it was visible in the femoral artery. Animals were then ﬁxed in Formalin
(10%) for 24 h before transfer to 70% ethanol for dissection and storage. Aortas
were then removed from the animals or dissected in situ for photography prior to
parafﬁnization and sectioning (7 µM). Slides were produced for tissue staining or
stained with standard stains including Elastin (Verhoeff-Van Gieson, Thermo
Scientiﬁc, MI, USA) or F-actin (ActinGreen™ 488 ReadyProbes, ThermoFisher
Scientiﬁc, USA) for quantitative analysis. Elastin integrity score was rated by
blinded observers and graded on an arbitrary scale of 5 (indicating high quality
elastic ﬁber) to 1 (indicating severe elastin fragmentation). For sequential ﬂuor-
escence in situ hybridization and immunoﬂuorescence microscopy aortas from
human and mice were cryosectioned using OCT standard protocol70.
Statistical analysis. Results are given as mean ± SD. Student’s test was applied to
determine the statistical signiﬁcance of difference between control and treated
groups (*p < 0.05, **p < 0.01 and ***p < 0.001). For all experiments at least three
replicates were performed. CLIP-seq reads were aligned to human UCSC h19 using
standard Illumina library-type. Cufﬂinks 2.0.2 was run on merged bam ﬁles to
assemble of transcripts and estimation of FPKM values. FPKM ≤ 1.0 cutoff was
used as detection threshold to generate the list of genes. One-way analysis of
variance (ANOVA) was used to analyze ultrasound and histology data involving
multiple mouse genotypes (95% conﬁdence interval is plotted). P-values represent
one-way ANOVA followed by Tukey’s honestly signiﬁcant difference (HSD) post-
hoc test. All graphs were produced using GraphPad Prism 7.0.
Data availability. All relevant data are available from authors. Genomic data from
CLIP-seq experiments was deposited to GEO under the access number GSE41607.
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